The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | CAR T-cell therapy in triple-class refractory myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, briefly comments on the treatment of triple-class refractory patients with multiple myeloma (MM), who continue to be challenging to manage in clinical practice. Dr Ramasamy highlights the potential of CAR T-cell therapy for treating this group of heavily pretreated patients, potentially in earlier lines of treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
